Trinity Biotech Plc - Company Profile
Powered by 
All the sales intelligence you need on Trinity Biotech Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Trinity Biotech Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Trinity Biotech Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Trinity Biotech Plc (Trinity Biotech) is biotechnology company that focuses on the development, acquisition, manufacturing, and marketing of diagnostic systems. The company’s product portfolio encompasses diagnostic tests and instruments that are used to detect hemoglobin A1c for diabetes monitoring and diagnosis, infectious diseases, autoimmune, sexually transmitted diseases, and liver and intestine disorders. Trinity Biotech markets its products through direct sales in the US, Brazil, Germany, France, and the UK; and through a network of distributors and strategic partnerships in other countries. The company has manufacturing facilities in the US, Brazil and Ireland. Trinity Biotech is headquartered in Bray, County Wicklow, Ireland.
Headquarters
Ireland
Address
Ida Business Park, Bray, Wicklow, A98H5C8
Website
www.trinitybiotech.com
Telephone
353 1 2769800
No of Employees
287
Industry
Medical Equipment
Ticker Symbol & Exchange
TRIB (NASD)
Revenue (2024)
$43.8M
-28.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-17.6%
(2024 vs 2023)
Market Cap*
$7.8M
Net Profit Margin (2024)
XYZ
-65.3%
(2024 vs 2023)
* As of and is in US$
Trinity Biotech Plc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Point-of-Care: | Laboratory Services | CGM+ |
| Uni-Gold HIV | UniGold | |
| Rapid Test Kits | Recombigen | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In February, the company secured local regulatory approval for commencement of upstream manufacturing activities of Uni-Gold HIV rapid test under its offshored and outsourced model. |
| 2025 | Regulatory Approval | In August, the company received approval from the in-country healthcare product regulatory authority for the commencement of its offshored and outsourced manufacturing of its flagship rapid HIV test. |
| 2025 | Regulatory Approval | In August, the company received approval from the New York State Department of Health (NYSDOH) to begin providing the FDA-cleared PreClara Ratio biomarker test for preeclampsia risk assessment. |
Competitor Comparison
| Key Parameters | Trinity Biotech Plc | Johnson & Johnson | Thermo Fisher Scientific Inc | Siemens Healthineers AG | Becton Dickinson and Co |
|---|---|---|---|---|---|
| Headquarters | Ireland | United States of America | United States of America | Germany | United States of America |
| City | Bray | New Brunswick | Waltham | Forchheim | Franklin Lakes |
| State/Province | Wicklow | New Jersey | Massachusetts | Bayern | New Jersey |
| No. of Employees | 287 | 138,200 | 125,000 | 72,000 | 72,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John Gillard | Chief Executive Officer; President; Director | Executive Board | 2020 | 45 |
| Eibhlin Kelly | Chief Information Officer | Senior Management | 2015 | - |
| Gary Keating, Ph.D | Chief Technology Officer | Senior Management | 2022 | 53 |
| Susan O’Connor | Interim Chief Financial Officer | Senior Management | 2025 | - |
| Jim Walsh, Ph.D. | Director; Director - Business Development | Executive Board | 2015 | 66 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer